
, Kazuhiko Fukatsu
, Satoshi Murakoshi
, Reo Inoue
, Kenichi Kono
, Midori Noguchi
, Nana Matsumoto
, Shoh Yajima
, Koichi Yagi
, Yoshifumi Baba

, Isao Miyajima
, Akira Tsukada
Citations


, Seong-Ho Kong
, Do Joong Park
, Han-Kwang Yang
, Jong Won Kim
, Ki Bum Park
, In Cho
, Sun-Hwi Hwang
, Dong-Wook Kim
, Su Mi Kim
, Seung-Wan Ryu
, Seong Chan Gong
, Pil Young Jung
, Hoon Ryu
, Sung Geun Kim
, Chang In Choi
, Dae-Hwan Kim
, Sung-IL Choi
, Ji-Ho Park
, Dong Jin Park
, Gyu-Yeol Kim
, Yunhee Choi
, Hyuk-Joon Lee
Citations

Although weight loss is an important factor for assessing the nutritional status, patient counselling or management is limited due to fewer studies on weight loss after colorectal cancer surgery.
Totally, 374 patients were included in the analysis (between August 2010 to December 2016). Patients’ weight was determined before surgery, and at 1 week, 6 weeks, 3 months, and 6 months after surgery. Change in weight was reviewed based on the gender and administration of chemotherapy. Severe weight loss is defined as greater than 5% weight loss after surgery.
The weight changes post-surgery at 1 week (−2.56±2.62 vs. −3.36±2.68, P<0.005), 6 weeks (−3.23±3.82 vs. −4.57±3.96, P=0.001), and 3 months (−0.93±5.01 vs. −2.79±4.86, P<0.001) were significantly greater in male subjects, as compared to female patients. However, at 6 months post-surgery, most patients showed weight gain with no statistical significance between the genders (1.11±4.64 vs. 1.94±6.26, P=0.143). Weight change based on treatment (with or without chemotherapy) reveal significant differences between the genders at 3 months post-surgery only (−1.33±4.65 vs. −2.52 ±5.15, P=0.027). Multivariate analysis for factors of severe weight loss show that the male gender [adjusted odds ratio (OR): 1.83, P=0.027)], adjuvant chemotherapy (adjusted OR 2.11, P=0.008), and presence of post-operative complications (adjusted OR 2.12, P=0.029) were significant factors.
In postoperative colorectal cancer patients, the weight and nutritional status require careful monitoring for at least 2 months after surgery, in order to prevent hindrance to chemotherapy. (Surg Metab Nutr 2019;10:-53)
Citations

